The following is a reconciliation of the weighted average shares outstanding used to compute basic and diluted net income (loss) per common share:


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Basic weighted average common shares outstanding		35,993,386		35,452,594		35,830,394		35,363,682
Effect of dilutive securities - equity compensation awards		536,170		371,272		795,225		—
Diluted weighted average common shares outstanding		36,529,556		35,823,866		36,625,619		35,363,682

Equity compensation awards for which total employee proceeds from exercise exceed the average fair value of the same equity incentive instrument over the period have an anti-dilutive effect on earnings per share during periods with net income, and accordingly, are excluded from diluted weighted average common shares outstanding. Anti-dilutive equity instruments of 604,861 and 1,272,897 were excluded from the diluted weighted average common shares outstanding for the three months ended June 30, 2026 and 2025, respectively. Anti-dilutive equity instruments of 484,814 were excluded from the diluted weighted average common shares outstanding for the six months ended June 30, 2026. Due to the net loss incurred during the six months ended June 30, 2025, the assumed exercise of all equity instruments was anti-dilutive and, therefore, not included in the net diluted loss per share calculations for that period.

No cash dividends were declared or paid during the three and six months ended June 30, 2026 and 2025.